TOLREMO therapeutics
Focused on the discovery and development of small molecules to prevent resistance in cancer therapy.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
* | CHF34.1m | Series A | |
| Total Funding | 000k | ||
| EUR | 2017 | 2018 |
|---|---|---|
| Revenues | 0000 | 0000 |
| % growth | - | 4 % |
| EBITDA | 0000 | 0000 |
| Profit | 0000 | 0000 |
| EV | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 |
Source: Company filings or news article
Related Content
TOLREMO Therapeutics is a biotechnology company focused on preventing resistance to cancer therapies. The company operates in the healthcare and pharmaceutical market, primarily serving patients with cancer and healthcare providers. TOLREMO's business model revolves around its proprietary drug discovery and development platform, which identifies novel drug resistance regulators and develops small molecule therapies to target these regulators. These therapies are designed to complement standard cancer treatments, aiming to improve response rates, extend survival times, and enhance the quality of life for patients. The company generates revenue through the development and commercialization of its proprietary therapies, as well as potential partnerships and licensing agreements with other pharmaceutical companies.
Keywords: cancer therapy, drug resistance, precision therapies, small molecule, drug discovery, biotechnology, healthcare, pharmaceutical, cancer patients, ETH Zurich spin-off.